Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Bio-Rad had revenues exceeding $2.5 billion in 2020. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 7,800 employees worldwide. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality.
With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. Please visit /cfxopusdx to learn more about Bio-Rad’s CFX Opus Dx Detection Systems for in vitro diagnostics.īio-Rad Laboratories, Inc. “Both systems are robust and secure platforms that leverage Bio-Rad’s long-standing expertise in genomic tools to better serve both research and clinical diagnostic markets,” he added.
DOWNLOAD BIO RAD CFX MANAGER SOFTWARE
“We continue to see an increasing demand for real-time PCR systems that offer more efficient workflows and improved data management and analysis that meets regulatory requirements in IVD assay development and testing, and we’re pleased to introduce the CFX Opus Dx Detection Systems to meet these needs,” said Steven Blakely, Director for Gene Expression and Software Technology, Bio-Rad. The systems provide precise quantification, improved thermal cycler performance, and the systems offer easy-to-use desktop management and analysis software with integrated security features. The CFX Opus 96 Dx Real-Time PCR System and the CFX Opus 384 Dx Real-Time PCR System are open systems that can multiplex up to five targets to provide efficient IVD assay development and testing. The systems offer accurate and precise quantification to improve assay development and workflow efficiencies and productivity for diagnostic testing and research.
The CFX Opus 96 Dx System and the CFX Opus 384 Dx System are the latest additions to Bio-Rad’s portfolio of real-time PCR instruments.
The CFX Opus 96 Dx System and the CFX Opus 384 Dx real-time PCR Systems offer accurate and precise quantification to improve IVD assay development and diagnostic testing
0 kommentar(er)
